www.3dsyndication.com - Dec 07, 2010

Co enters into a MoU with Paragon Steels Pvt Ltd for purchase of its injectibles equipment for Rs1.5 crore

Gujarat-based, Marck Biosciences Ltd has acquired a large volume injectible facility in Goa and will step up its manufacturing capacity by over 33% for large volume injectibles by March 2011. Marck has acquired the assets of Goa-based Ravish Infusion on a lock-stock-barrel basis for Rs5.47 crore under auction process from Debt Recovery Tribunal II, Mumbai.

Company has also entered into a MoU with Coimbatore-based Paragon Steels Pvt Ltd for purchase of its injectibles equipment for Rs1.5 crore. Company plans to set up these equipments at the Goa facility.

The company manufacturers and markets sterile liquids pharmaceutical dosages, using the Blow-Fill-Seal (BFS) technology.  Bhavesh Patel, MD, Marck Biosciences said, "Company is operating above 90% capacity for last 3 years in large volume injectibles. The acquisitions will help Marck Biosciences expand capacity to meet the growing demand. With these two acquisitions, the total capacity for large volume injectibles will increase by 200 lakh bottles per year."

The Goa facility will enable Marck to manufacture large volume parenterals having Euroheads, which Company proposes to market in South-East Asia, East & West Africa and CIS countries. Presently at its Kheda facility, Marck has an installed capacity to manufacture large volume parenterals of 596 lakh bottles per annum as well as small volume parenterals of 2,265 lakhs vials per annum.

Company has recently filed DRHP with Sebi. The co...